Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clinical Decision-Making | 2 | 2020 | 267 | 1.130 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2020 | 87 | 0.800 |
Why?
|
| Mitral Valve Stenosis | 1 | 2019 | 21 | 0.650 |
Why?
|
| Probability | 1 | 2020 | 289 | 0.650 |
Why?
|
| Likelihood Functions | 1 | 2019 | 126 | 0.650 |
Why?
|
| Endocarditis, Bacterial | 1 | 2019 | 36 | 0.640 |
Why?
|
| Echocardiography, Doppler | 1 | 2019 | 92 | 0.630 |
Why?
|
| Research Personnel | 1 | 2020 | 151 | 0.620 |
Why?
|
| Data Interpretation, Statistical | 1 | 2020 | 323 | 0.610 |
Why?
|
| Dabigatran | 1 | 2018 | 22 | 0.610 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 245 | 0.610 |
Why?
|
| ROC Curve | 1 | 2019 | 447 | 0.600 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 139 | 0.580 |
Why?
|
| Biomedical Research | 1 | 2020 | 585 | 0.460 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 325 | 0.450 |
Why?
|
| Stroke | 2 | 2019 | 1015 | 0.450 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 1477 | 0.430 |
Why?
|
| Internship and Residency | 1 | 2022 | 941 | 0.420 |
Why?
|
| Heart Failure | 2 | 2020 | 1962 | 0.350 |
Why?
|
| Bayes Theorem | 2 | 2022 | 331 | 0.330 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2016 | 46 | 0.260 |
Why?
|
| Ventricular Function, Left | 2 | 2016 | 469 | 0.210 |
Why?
|
| Aortic Valve | 2 | 2016 | 399 | 0.200 |
Why?
|
| Problem Solving | 1 | 2022 | 141 | 0.190 |
Why?
|
| Critical Pathways | 1 | 2021 | 74 | 0.180 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 55 | 0.180 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2020 | 12 | 0.170 |
Why?
|
| Furosemide | 1 | 2020 | 32 | 0.170 |
Why?
|
| Receptors, Atrial Natriuretic Factor | 1 | 2019 | 3 | 0.170 |
Why?
|
| Humans | 18 | 2022 | 115052 | 0.170 |
Why?
|
| Troponin | 1 | 2019 | 44 | 0.170 |
Why?
|
| Streptococcus mutans | 1 | 2019 | 8 | 0.170 |
Why?
|
| Multimorbidity | 1 | 2019 | 33 | 0.160 |
Why?
|
| Conservative Treatment | 1 | 2019 | 29 | 0.160 |
Why?
|
| Cryoglobulins | 1 | 2018 | 7 | 0.160 |
Why?
|
| Mycoplasma Infections | 1 | 2018 | 13 | 0.160 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 45 | 0.160 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2019 | 44 | 0.160 |
Why?
|
| Rheumatic Diseases | 1 | 2019 | 49 | 0.160 |
Why?
|
| Middle Aged | 6 | 2021 | 26831 | 0.150 |
Why?
|
| Patient Safety | 1 | 2021 | 277 | 0.150 |
Why?
|
| Inpatients | 1 | 2021 | 378 | 0.150 |
Why?
|
| Educational Measurement | 1 | 2019 | 257 | 0.150 |
Why?
|
| Streptococcal Infections | 1 | 2019 | 127 | 0.140 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 235 | 0.140 |
Why?
|
| Warfarin | 1 | 2018 | 135 | 0.140 |
Why?
|
| Hepatitis C | 1 | 2019 | 226 | 0.130 |
Why?
|
| Treatment Outcome | 6 | 2022 | 9123 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2021 | 2976 | 0.130 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 233 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2021 | 767 | 0.120 |
Why?
|
| Male | 9 | 2021 | 55737 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 1715 | 0.120 |
Why?
|
| Arterio-Arterial Fistula | 1 | 2014 | 4 | 0.120 |
Why?
|
| Coronary Aneurysm | 1 | 2014 | 11 | 0.120 |
Why?
|
| Ventricular Remodeling | 1 | 2016 | 227 | 0.120 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2014 | 30 | 0.110 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2016 | 152 | 0.110 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2016 | 174 | 0.110 |
Why?
|
| Anticoagulants | 1 | 2018 | 546 | 0.110 |
Why?
|
| Incidental Findings | 1 | 2014 | 76 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2019 | 899 | 0.110 |
Why?
|
| Heart Block | 1 | 2012 | 38 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 361 | 0.100 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2018 | 445 | 0.100 |
Why?
|
| Aortic Valve Stenosis | 1 | 2016 | 272 | 0.100 |
Why?
|
| Cardiac Catheterization | 1 | 2016 | 535 | 0.100 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2012 | 42 | 0.100 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 930 | 0.100 |
Why?
|
| Heart Conduction System | 1 | 2012 | 82 | 0.100 |
Why?
|
| Mitral Valve | 1 | 2012 | 86 | 0.100 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 1812 | 0.100 |
Why?
|
| Heart Valve Diseases | 1 | 2012 | 161 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 4420 | 0.090 |
Why?
|
| Aged | 5 | 2020 | 19122 | 0.090 |
Why?
|
| Catheter Ablation | 1 | 2012 | 291 | 0.080 |
Why?
|
| Adult | 5 | 2022 | 30658 | 0.080 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2012 | 413 | 0.080 |
Why?
|
| Female | 6 | 2021 | 59619 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 814 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 1080 | 0.050 |
Why?
|
| Time Factors | 3 | 2016 | 6142 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 6357 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2019 | 12548 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2022 | 616 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 332 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2021 | 234 | 0.040 |
Why?
|
| Vibration | 1 | 2019 | 61 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 2551 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 412 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 1665 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 476 | 0.040 |
Why?
|
| Cold Temperature | 1 | 2018 | 129 | 0.040 |
Why?
|
| Risk Factors | 3 | 2016 | 8642 | 0.040 |
Why?
|
| Fibrosis | 1 | 2019 | 454 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1457 | 0.030 |
Why?
|
| Diastole | 1 | 2016 | 131 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2021 | 606 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 676 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 2016 | 121 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 2894 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2016 | 510 | 0.030 |
Why?
|
| Voltage-Sensitive Dye Imaging | 1 | 2012 | 4 | 0.030 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2012 | 70 | 0.030 |
Why?
|
| Algorithms | 1 | 2019 | 1489 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2799 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 575 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2014 | 307 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 498 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 1132 | 0.020 |
Why?
|
| Hospitalization | 1 | 2019 | 1755 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 941 | 0.020 |
Why?
|
| Action Potentials | 1 | 2012 | 406 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2012 | 562 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 3419 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 4411 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1812 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2341 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3118 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 17866 | 0.010 |
Why?
|